[Federal Register Volume 66, Number 106 (Friday, June 1, 2001)]
[Notices]
[Pages 29824-29825]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-13846]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA-3071-N]


Medicare Program; Meeting of the Drugs, Biologics, and 
Therapeutics Panel of the Medicare Coverage Advisory Committee--June 
20, 2001

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a public meeting of the Drugs, 
Biologics, and Therapeutics Panel (the Panel) of the Medicare Coverage 
Advisory Committee. The Panel provides advice and recommendations to us 
about clinical issues. The Panel will hear and discuss presentations 
from interested persons regarding the use of levo-carnitine in end 
stage renal disease patients.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)).

DATES: The Meeting: June 20, 2001 from 8 a.m. until 4:30 p.m. E.D.T.
    Deadline for Presentations and Comments: June 13, 2001, 5 p.m., 
E.D.T.
    Special Accommodations: Persons attending the meeting who are 
hearing or visually impaired, or have a condition that requires other 
special assistance or accommodations, are asked to notify the Executive 
Secretary by June 6, 2001 (see FOR FURTHER INFORMATION CONTACT).

ADDRESSES: The Meeting: The meeting will be held at The Baltimore 
Convention Center, Rooms 321 and 322, One West Pratt Street, Baltimore, 
MD 21201.
    Presentations and Comments: Submit formal presentations and written 
comments to Kimberly A. Long, Executive Secretary; Office of Clinical 
Standards and Quality; Health Care Financing Administration; 7500 
Security Boulevard; Mail Stop S3-02-01; Baltimore, MD 21244.
    Website: You may access up-to-date information about this meeting 
at www.hcfa.gov/coverage.
    Hotline: You may access up-to-date information about this meeting 
on the HCFA Advisory Committee Information Hotline, 1-877-449-5659 
(toll free) or in the Baltimore area (410) 786-9379.

FOR FURTHER INFORMATION CONTACT: Kimberly A. Long, Executive Secretary, 
410-786-5702.

SUPPLEMENTARY INFORMATION: On August 13, 1999, we published a notice 
(64 FR

[[Page 29825]]

44231) announcing an earlier meeting of the Drugs, Biologics, and 
Therapeutics Panel (the Panel) and also describing the Medicare 
Coverage Advisory Committee (MCAC), which provides advice and 
recommendations to us about clinical issues. This notice announces the 
June 20, 2001 public MCAC meeting of the Drugs, Biologics, and 
Therapeutics Panel.

Current Panel Members

    Thomas V. Holohan, M.A., M.D., FACP; Leslie P. Francis, JD, Ph.D.; 
Judith A. Cahill, M.A.; Michael L. Friedland, M.D.; Kathy J. 
Helzlsouer, M.D., M.H.S.; Robert C. Johnson, M.S.; Ronald P. Jordan, 
R.Ph.; Mitchell Sugarman, M.B.A., M.S.; Cathleen M. Dooley, M.A.; 
Christine M. Grant, JD.

Meeting Topic

    The Panel will hear and discuss presentations from interested 
persons regarding the use of levo-carnitine in end stage renal disease 
patients.

Procedure and Agenda

    This meeting is open to the public. The Panel will hear oral 
presentations from the public for approximately 2.5 hours. The Panel 
may limit the number and duration of oral presentations to the time 
available. If you wish to make formal presentations you must notify the 
Executive Secretary named in the FOR FURTHER INFORMATION CONTACT 
section of this notice. In addition, you must submit the following by 
the Deadline for Presentations and Comments date listed in the DATES 
section of this notice: a brief statement of the general nature of the 
evidence or arguments you wish to present and the names and addresses 
of proposed participants; and a written copy of your presentation to 
the Executive Secretary before the meeting. We will request that you 
declare at the meeting whether or not you have any financial 
involvement with manufacturers of any items or services being discussed 
(or with their competitors).
    After the public and our presentations, the Panel will deliberate 
openly on the topic. Interested persons may observe the deliberations, 
but the Panel will not hear further comments during this time except at 
the request of the chairperson. The Panel will also allow approximately 
a 30-minute open public session for any attendee to address issues 
specific to the topic. At the conclusion of the day, the members will 
vote and the Panel will make its recommendation.

    Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).


(Catalog of Federal Domestic Assistance Program No. 93.774, 
Medicare--Supplementary Medical Insurance Program)
    Dated: May 25, 2001.
Jeffrey L. Kang, M.D.,
Director, Office of Clinical Standards and Quality, Health Care 
Financing Administration.
[FR Doc. 01-13846 Filed 5-31-01; 8:45 am]
BILLING CODE 4120-01-P